addiction-implant-fda.jpeg - Washington Times
Skip to content

This undated photo provided by Braeburn Pharmaceuticals shows the Probuphine opioid implant. Federal health officials on Thursday, May 26, 2016, approved the innovative new option for Americans struggling with addiction to heroin and painkillers: a drug-oozing implant that curbs craving and withdrawal symptoms for six months at a time. The implant is essentially a new, long-term delivery system for an established drug, buprenorphine, which has long been used to treat opioid addiction. (Braeburn Pharmaceuticals via AP)

This undated photo provided by Braeburn Pharmaceuticals shows the Probuphine opioid implant. Federal health officials on Thursday, May 26, 2016, approved the innovative new option for Americans struggling with addiction to heroin and painkillers: a drug-oozing implant that curbs craving and withdrawal symptoms for six months at a time. The implant is essentially a new, long-term delivery system for an established drug, buprenorphine, which has long been used to treat opioid addiction. (Braeburn Pharmaceuticals via AP)

Featured Photo Galleries